Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:



Advertisements
Similar presentations
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Advertisements

Figure 2 Exosome composition
Figure 4 The gut microbiota directly influences T-cell differentiation
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 1 Patients cured of HCV infection
Figure 2 The three most commonly performed bariatric surgical procedures Figure 2 | The three most commonly performed bariatric surgical procedures. a.
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Gut microorganisms at the intersection of several diseases
Figure 5 Lipid droplet consumption
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 The microbiome–gut–brain axis
Figure 3 The T-cell cytokine tree in IBD
Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Figure 1 Towards precision PRRT for neuroendocrine tumours
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process
Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Giant lipid droplet formation
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Schematic outlining the results of Buffington et al.
Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.
Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Figure 1 Definition and concept of ACLF
Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Surgical step-up approach
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Endoscopic step-up approach
to the liver and promote patient-derived xenograft tumour growth
Figure 7 Example colonic high-resolution manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Environmental factors contributing to IBD pathogenesis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.
Figure 1 Median coverage and distribution by
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Possible therapeutic targets to decrease hepatic steatosis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Strategies to improve liver regeneration
Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 New therapeutic approaches in IBD with their specific targets
Figure 5 Systems biological model of IBS
Figure 4 Local species pools that contribute to the
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Lifelong influences on the gut microbiome from
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Classifications and appearance of CCAs
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence.
Figure 1 The spread of colorectal cancer metastases
Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.49 Figure 3 Schematic representation of the two main parallel pathways of excitatory and inhibitory neurotransmission of the enteric nervous system in the human LES Permission obtained from Lecea B, Thesis, Universitat Autònoma de Barcelona (2013) and John Wiley and Sons © Farre, D & Sifrim, D. Brit. J. Phharmacol. 153, 858–869 (2008)118 Clavé, P. & Shaker, R. (2015) Dysphagia: current reality and scope of the problem Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.49